Table 1.

Nanoparticle derived drugs in the different phase of clinical development

Product	Type of nano materials	Size (nm)	Application	Route of administration	Phase	company
Combidex (Ferumoxtran-10)	Iron oxide nanoparticles	17–20	Tumor imaging	IV	NDA field	Advanced Magnetics
Biovant	Nano sized calcium phosphate	NAD	Vaccine component	IM	Phase I completed	BioSante Pharmaceutical
CYT-6091 (Aurimmune)	TNF-α bound PEGlyated colloidal gold particle	33	Solid tumors	IV	Phase I	Cytlmmune Sciences
Bioconjugated nanoparticles	Luminescent quantum dots	10–15	Cancer imaging	Subc	Preclinical	Emory-Georgia tech nanotechnology centre
Abraxane	Albumin-bound paclitaxel particles	130	NSC lung cancer, breast cancer, others	IV	Approved	Abraxis Oncology

Abbreviations: IV= Intravenous; IM= Intramuscular, NAD=No Available Data Subc= Subcutaneous

Adopted from Reference194.